...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
【24h】

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.

机译:非酒精性脂肪性肝炎患者噻唑烷二酮治疗期间脂肪组织胰岛素抵抗变化对组织学反应的重要性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Pioglitazone treatment improves insulin resistance (IR), glucose metabolism, hepatic steatosis, and necroinflammation in patients with nonalcoholic steatohepatitis (NASH). Because abnormal lipid metabolism/elevated plasma free fatty acids (FFAs) are important to the pathophysiology of NASH, we examined the impact of pioglitazone therapy on adipose tissue insulin resistance (Adipo-IR) during the treatment of patients with NASH. To this end, we assessed glucose/lipid metabolism in 47 patients with impaired glucose tolerance/type 2 diabetes mellitus and NASH and 20 nondiabetic controls. All individuals underwent a 75-g oral glucose tolerance test (OGTT) in which we measured glucose tolerance, IR, and suppression of plasma FFAs. We also measured Adipo-IR index (fasting, FFAs x insulin), hepatic fat by magnetic resonance spectroscopy, and liver histology (liver biopsy). Patients were randomized (double-blind) to diet plus pioglitazone (45 mg/day) or placebo for 6 months, and all measurements were repeated. We found that patients with NASH had severe Adipo-IR and low adiponectin levels. Fasting FFAs were increased and their suppression during the OGTT was impaired. Adipo-IR was strongly associated with hepatic fat (r= 0.54) and reduced glucose clearance both fasting (r=0.34) and during the OGTT (r=0.40, all P <0.002). Pioglitazone significantly improved glucose tolerance and glucose clearance, steatosis and necroinflammation (all P<0.01-0.001 versus placebo). Fasting/postprandial plasma FFAs decreased to levels of controls with pioglitazone (P<0.02 versus placebo). Adipo-IR decreased by 47% and correlated with the reduction of hepatic fat (r=0.46, P=0.009) and with the reduction in hepatic necroinflammation (r=0.47, P=0.0007). CONCLUSION: Patients with NASH have severe Adipo-IR independent of the degree of obesity. Amelioration of Adipo-IR by pioglitazone is closely related to histological improvement and plays an important role during treatment of patients with NASH.
机译:吡格列酮治疗可改善非酒精性脂肪性肝炎(NASH)患者的胰岛素抵抗(IR),葡萄糖代谢,肝脂肪变性和坏死性炎症。因为异常的脂质代谢/血浆游离脂肪酸(FFA)异常对NASH的病理生理很重要,所以我们检查了吡格列酮治疗对NASH患者治疗期间脂肪组织胰岛素抵抗(Adipo-IR)的影响。为此,我们评估了47名糖耐量受损/ 2型糖尿病和NASH患者以及20位非糖尿病对照患者的葡萄糖/脂质代谢。所有个体均接受75克口服葡萄糖耐量测试(OGTT),其中我们测量了葡萄糖耐量,IR和血浆FFA抑制。我们还测量了Adipo-IR指数(空腹,FFA x胰岛素),磁共振波谱测定的肝脂肪和肝组织学(肝脏活检)。患者随机(双盲)饮食加吡格列酮(45 mg /天)或安慰剂治疗6个月,并重复所有测量。我们发现NASH患者患有严重的Adipo-IR和低脂联素水平。空腹FFA增加,并且在OGTT期间其抑制作用减弱。 Adipo-IR与肝脂肪(r = 0.54)密切相关,并且在禁食(r = 0.34)和OGTT期间(r = 0.40,所有P <0.002)均降低了葡萄糖清除率。吡格列酮显着改善了葡萄糖耐量和葡萄糖清除率,脂肪变性和坏死性炎症(与安慰剂相比,所有P <0.01-0.001)。空腹/餐后血浆FFA降至吡格列酮对照组(P <0.02,相对于安慰剂)。 Adipo-IR降低47%,并与肝脂肪减少(r = 0.46,P = 0.009)和肝坏死性炎症减少(r = 0.47,P = 0.0007)相关。结论:NASH患者患有严重的Adipo-IR,与肥胖程度无关。吡格列酮改善Adipo-IR与组织学改善密切相关,在NASH患者的治疗中起着重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号